Eli Lilly has launched Mounjaro, a first-of-its-kind drug for obesity and type 2 diabetes, in India. This medication, approved by CDSCO, helps with weight management and activates hormone receptors.

Eli Lilly and Company launched its weight loss drug Mounjaro in India on Thursday after obtaining approval from the Central Drugs Standard Control Organisation (CDSCO). This is a drug which ...

Dr Reddy’s Laboratories is also working on a generic version of Wegovy. (Image/Getty) US pharma major Eli Lilly on Thursday launched its global bestseller anti-obesity and diabetes drug Mounjaro ...

American pharmaceutical major Eli Lilly and Company on Thursday (March 20, 2025) launched its diabetes and obesity management drug Mounjaro (tirzepatide) in India. The company launched the drug in ...

With diabetes and obesity cases surging in India, pharmaceutical giant Eli Lilly and Company (India) has launched Mounjaro (tirzepatide), a once-weekly injectable drug for chronic weight ...

India has taken a major step in the fight against obesity and diabetes with the launch of Mounjaro, a groundbreaking drug from American pharmaceutical giant Eli Lilly and Co. The company announced ...

Approved by the Central Drugs Standard Control Organization (CDSCO), Mounjaro® is available in single-dose vials, with pricing set at Rs3,500 for a 2.5 mg vial and Rs4,375 for a 5 mg vial ...

Tirzepatide was evaluated in two robust global clinical development programs. (Image Credits: Pexels) Eli Lilly and Company (India) on Thursday announced the launch of Mounjaro in single-dose vial ...

Obesity is linked to more than 200 health complications, including hypertension The 2.5 mg vial is priced at 3,500 rupees ($40.5) and the 5 mg vial is priced at 4,375 rupees. Bloomberg Follow ...

New Delhi [India], March 20 (ANI): Global pharmaceutical company Eli Lilly and Company (India) has introduced Mounjaro (tirzepatide) in India, a breakthrough drug for the treatment of Type 2 ...

Investing.com -- U.S. pharmaceutical company Eli Lilly (NYSE:LLY) has introduced its diabetes and weight-loss drug Mounjaro in India, ahead of its competitor Novo Nordisk (NYSE:NVO). This comes as ...

Investors with a lot of money to spend have taken a bearish stance on Eli Lilly LLY. And retail traders should know. We noticed this today when the trades showed up on publicly available options ...